10 Best Biotech Companies in India | 2025

Biotechnology is a fast-growing industry that applies biological systems, organisms, or their derivatives to create new products and technologies in industries such as healthcare, agriculture, and environmental science. From vaccines that save lives to genetically modified foods and industrial enzymes, biotechnology is the foundation for numerous revolutionary advances defining the contemporary world.

India is one of the world’s top 12 biotech hubs and the third-largest biotech hub in the Asia-Pacific region. With more than 5,000 biotech firms, numerous MNC Companies in India, and a sound base of research in academic circles, India’s biotechnology sector is geared for huge growth. The India Brand Equity Foundation (IBEF) estimates that the Indian biotechnology industry stood at USD 92.3 billion as of 2023, and will grow to USD 150 billion by 2025, with a CAGR of 12-14%. Programs such as Startup India, BIRAC (Biotechnology Industry Research Assistance Council), and the Biotech Startup Policy have only added fuel to fire in this arena.

Whether you’re a student researching career opportunities, an investor seeking high-growth industries, or a candidate hoping to work in pioneering industries, being aware of Indian biotech’s major players can unlock new doors. In this blog, we feature the top 10 biotech companies in India that are leading innovation and global influence.

Overview on the Biotech Industry in India

India’s biotechnology sector is among the most vibrant and fast-growing industries in the nation, contributing significantly to healthcare, agriculture, and industrial advancement. Supported by a robust scientific foundation, government support, and a fast-growing startup culture, the sector is now an international hub for biotech research and development.

Market Size and Key Segments

The Indian biotech industry is worth USD 92.3 billion as of 2023 and is estimated to reach USD 150 billion by 2025, with a 12–14% annual growth rate. The biotechnology industry is widely divided into five primary segments:

• Bio-Pharma: Represents approximately 60% of the biotech industry, with an emphasis on vaccines, therapeutics, and diagnostics. India is a vaccine hub of the world, exporting to more than 150 nations.
• Bio-Agriculture: Involves genetically engineered crops, bio-fertilizers, and sustainable agriculture technologies.
• Bio-Industrial: Involves biofuels, biodegradable plastics, and other environmentally friendly technologies with the objective of decreasing environmental footprints.
• Bio-Services: Involves contract research organizations (CROs), clinical trials, and R&D outsourcing for international pharmaceutical companies.
• Bio-IT (Bioinformatics): Combines biotechnology with computational software to speed up drug discovery, genomics, and personalized medicine.

Key Government Initiatives

The Indian government has been instrumental in fostering the biotech environment via committed policies and funding schemes:

• Department of Biotechnology (DBT): The nodal agency under the Ministry of Science & Technology, for formulating biotech policies and funding research.
• BIRAC (Biotechnology Industry Research Assistance Council): A DBT-supported program offering seed money, mentoring, and incubation facilities to startups and small and medium enterprises (SMEs).
• National Biotech Strategy: Seeks to develop a world-class biotech ecosystem through skill acquisition, infrastructure development, and collaborative R&D.
• Startup India and Make in India: Promote indigenous innovation and production in the area of biotechnology.

Biotech Hubs in India

India’s biotech ecosystem is spatially dispersed, with some of the high-achieving clusters:

• Bengaluru (Karnataka): Popularly referred to as the “Biotech Capital of India” with companies like Biocon, Syngene, and more than 190 biotech companies.
• Hyderabad (Telangana): A key hub for vaccine production, research, and life sciences innovation.
• Pune (Maharashtra): Home to biotech firms, research institutions, and start-ups, particularly agri-biotech and bio-industrial.
• Other growing hubs are Ahmedabad, Chennai, and Delhi-NCR.

Role of R&D and Public-Private Partnerships

Innovation has been the driving force behind India’s biotech success. Substantial investments in R&D infrastructure, combined with a growing number of collaborative activities between academia, government, and industry, have speeded up the development of new biotechnologies. Research institutions such as CSIR, ICMR, and IITs have close collaborations with private sector companies to fill the space between research and commercialization.

The establishment of biotech parks and incubation hubs, including C-CAMP (Centre for Cellular and Molecular Platforms) in Bengaluru and IKP Knowledge Park in Hyderabad, has further facilitated early-stage innovation and development of talent.

List of Top 10 Biotech Companies in India

1. Dr. Reddy’s Laboratories 

Established in 1984 by Dr. K. Anji Reddy at Hyderabad, Dr. Reddy’s Laboratories is a multi-divisional biopharma with the vision of developing affordable and innovative therapies globally.

Operating in more than 50 countries, well-established R&D infrastructure (8 global R&D centers), and integrated capabilities across APIs, generics, biosimilars, differentiated formulations, and consumer health, Dr. Reddy’s is renowned for making healthcare access possible through scientific excellence

Key Products/Services:

• Active Pharmaceutical Ingredients (APIs): Supplies complex, high-purity APIs including steroids, oncology molecules, and peptides.
• Generic Formulations: Offers a wide range of generics in regulated markets like the US and Europe, and branded generics in India (e.g., Omez, Norilet).
• Biosimilars: Offers affordable biologics such as Darbepoetin alfa (Cresp®) and Trastuzumab (Hervycta®).
• Contract Services & Drug Delivery: Provides global pharmaceutical companies with custom research and development services.
• COVID-19 Therapies & Vaccines: Developed and marketed treatments like Favipiravir, Remdesivir, Molnupiravir, and partnered on the Sputnik V vaccine in India.

Key Achievements or Milestones:

• 1984: Began operations with the manufacture of APIs.
• 1991: Launched Omez (omeprazole), one of India’s top-selling branded generics.
• 2001: Became the first Asia-Pacific pharmaceutical company (outside Japan) to list on the New York Stock Exchange.
• 2007–2010: Launched India’s first biosimilar Darbepoetin alfa (Cresp®) and Trastuzumab (Hervycta®).
• 2012: Acquired Netherlands-based OctoPlus to strengthen drug delivery capabilities.
• 2020–2021: Played a key role in India’s COVID-19 response with antiviral drugs and vaccine collaborations.
• 2022–2024: Recognized globally for sustainable practices, advanced manufacturing (Industry 4.0), and listed among the world’s top pharma employers.

2. Biocon Ltd.

Founded in 1978 by Kiran Mazumdar-Shaw in Bengaluru, Biocon Ltd. is a pioneer of the Indian biotechnology industry and a worldwide biopharmaceutical leader. What started as a modest enzyme production company has evolved into a multinational corporation driven by accessible healthcare through quality biosimilars, generics, and new biologics.

With operations in more than 120 countries, Biocon is dedicated to changing the face of global health by making complicated drugs available to patients all over the world. 

Key Products/Services:

• APIs & Generics: Specializes in complex active pharmaceutical ingredients and generic formulations, including statins, immunosuppressants, and oncology products.
• Biosimilars: Offers a wide range of biosimilars such as insulin glargine, trastuzumab, pegfilgrastim, adalimumab (Hulio®), and ustekinumab (Yesintek™), approved in major global markets.
• Novel Biologics: Develops innovative biologics like nimotuzumab (BIOMAb-EGFR®) for cancer treatment and itolizumab (ALZUMAb®) for autoimmune diseases.
• Contract Research (Syngene): Provides end-to-end research and development services through its subsidiary, Syngene International.
• Clinical Development: Offers clinical trial services across phases I to IV through Clinigene.

Key Achievements or Milestones:

• 1978: Founded as India’s first enzyme manufacturing company.
• 2001: First Indian firm to receive USFDA approval for Lovastatin API.
• 2003: Launched recombinant human insulin using proprietary technology.
• 2006: Introduced BIOMAb-EGFR®, a novel biologic for cancer.
• 2009: Entered a global biosimilar partnership with Mylan.
• 2010: Expanded international manufacturing with a large insulin facility in Malaysia.
• 2014–2017: Gained approvals for biosimilars in the US, EU, and Japan.
• 2020: Received emergency use authorization for itolizumab in COVID-19 treatment.
• 2022: Acquired the global biosimilar business of Viatris, significantly boosting its international footprint.
• 2024: Launched ustekinumab biosimilar in the US and surpassed $1 billion in annual biosimilar revenues.

3. Syngene International Ltd.

Established in 1993, Syngene International Ltd. is India’s leading contract research, development, and manufacturing organization (CRDMO). Part of Biocon and with headquarters in Bengaluru, Syngene engages with global customers in the pharmaceutical, biotech, animal health, consumer goods, and specialty chemicals industries.

Employing more than 8,000 people, of which over 5,600 are scientists, the company offers integrated and tailored scientific solutions from early discovery to commercial production.

Key Products/Services:

• Discovery Services: Offers end-to-end early-stage research in chemistry, biology, safety assessment, and cutting-edge therapeutic areas such as peptides, oligonucleotides, ADCs, and PROTACs.
• Dedicated R&D Centers: Operates exclusive research labs for long-term partnerships with major global firms, delivering tailored solutions and scientific innovation.
• Development Services: Supports drug development with services like preclinical evaluation, formulation development, process optimization, and analytical testing.
• Manufacturing Services: Provides cGMP-compliant manufacturing for small molecules and biologics, including capabilities in microbial and mammalian systems, sterile fill-finish, and emerging technologies like mRNA and plasmid DNA.

Key Achievements or Milestones:

• Built world-class manufacturing facilities in Bengaluru and Mangalore approved by global regulators including the US FDA, EMA, and MHRA.
• Extended multi-year partnerships with leading pharmaceutical companies such as Amgen, Bristol Myers Squibb, and Zoetis.
• Established a state-of-the-art facility to manufacture Librela®, a biologic used for treating canine osteoarthritis.
• Launched specialized infrastructure for technologies such as PROTACs and antibody-drug conjugates, and incorporated AI platforms to accelerate drug discovery.
• Expanded its client base to include over 400 companies, including 8 of the top 10 global pharma companies.

4. Intas Pharmaceuticals Ltd.

Founded in 1977 and with its headquarters in Ahmedabad, Intas Pharmaceuticals Ltd. is a top Indian pharma company with a strong global presence. The organization is famous for its vertically integrated operations, from active pharmaceutical ingredients (APIs) to finished dosage forms and biologics.

Through its international division, Accord Healthcare, Intas markets a wide portfolio of generics, biosimilars, and specialty drugs in more than 85 countries. With over 19,000 workers, Intas has always had strong growth in domestic as well as international markets.

 Key Products/Services:

• Formulations & Generics: Offers a wide spectrum of oral and injectable medicines, including novel drug delivery systems (NDDS), for multiple therapeutic areas.
• Biosimilars & Biologics: Among the pioneers in India’s biosimilar segment, producing EU-approved biosimilars like filgrastim using microbial and mammalian expression systems.
• APIs & Vertical Integration: Manufactures critical oncology and non-oncology APIs, supporting global filings with proprietary technology and lifecycle management strategies.
• R&D & Innovation: Employs over 550 scientists and focuses on drug discovery, oncology research, advanced delivery technologies, and development of new chemical entities.

Key Achievements or Milestones:

• Became the first Indian company to receive EU-GMP approval for a biologics facility in 2007.
• Commercialized its first biosimilar, filgrastim, in Europe in 2015.
• Operates 14 manufacturing sites globally, including units in India, the UK, and Mexico—all approved by major global regulators like US FDA, EMA, and MHRA.
• Ranks among the top 10 pharmaceutical companies in India, with a growing market share and leadership in therapies like CNS, cardiology, oncology, and immunology.
• Achieved significant international expansion through the acquisition of Actavis UK & Ireland in 2016.
• Recognized with a Guinness World Record in 2022 for conducting a large-scale health awareness initiative.

5. GSK Pharmaceuticals India

GSK Pharmaceuticals India, a subsidiary of the global healthcare giant GSK, has been a significant contributor to India’s pharma story for more than 90 years. Having its headquarters in Mumbai and a significant manufacturing site in Nashik, the organization is well recognized for its robust portfolio in vaccines, general medicines, and specialty treatments.

GSK integrates global scientific excellence with local market understanding to provide high-quality, affordable healthcare solutions. A legacy of public health and innovation, GSK India is committed to further enhancing the health outcomes in the country.

Key Products/Services:

• Vaccines: Offers a diversified portfolio covering infants to adults, including flu, hepatitis, meningitis, and shingles vaccines. Holds the top position in India’s self-pay vaccine market.
• General Medicines: Produces a range of therapies in anti-infectives, dermatology, pain management, gastroenterology, and vitamins.
• Specialty Therapies: Provides advanced treatments for areas like respiratory diseases, oncology, immunology, and HIV.
• R&D & Innovation Hub: Utilizes modern genomics, AI/ML, and other advanced platforms to discover and develop new therapies, supported by both global and India-based R&D centers.
• Commercial & Distribution Network: Features a robust network that includes a manufacturing unit, 20+ contract manufacturing partners, 26 warehouses, and around 6,000 stockists, ensuring wide reach across India.

Key Achievements or Milestones:

• Operates since 1924 in India and has built a legacy of trust and innovation.
• Celebrated its 100th annual report, symbolizing long-standing commitment to healthcare.
• Recognized for leadership in vaccines, general medicines, and specialty therapies.
• Awarded numerous accolades, including Sustainability Excellence, Marketing and Sales Awards from OPPI, Best Employing Employer for Women, and Great Place to Work certifications.
• Consistently topped the Access to Medicine Index for its efforts in affordable healthcare.
• Hosts a world-class Global Capability Center in Bengaluru catering to digital and commercial excellence.

6. Zydus Cadila

Zydus Cadila, now Zydus Lifesciences Ltd., is India’s most valued and innovation-centric pharma company, boasting a heritage dating back to 1952. Based in Ahmedabad, the organization has grown from a local formulations firm to a globally admired, fully integrated life sciences company. Its activities cover the entire pharma value chain—ranging from research and development, production, and marketing of generic formulations, complex APIs, biosimilars, vaccines, new biologics, and wellness products.

Zydus is also a trailblazer in some major biotech breakthroughs in India, including introducing the nation’s first indigenously created DNA-based COVID-19 vaccine (ZyCoV-D) and biosimilar adalimumab (Exemptia) for autoimmune disorders. 

Key Products/Services:

• Formulations & Generics: Offers a broad portfolio of oral solids, injectables, transdermals, and metered-dose inhalers, serving diverse therapeutic areas.
• Biosimilars & Biologics: Pioneers in India’s biotech revolution; first to launch adalimumab biosimilar (Exemptia) and rheumatic disease mAbs. Strong biologics pipeline includes monoclonal and rabies antibody therapies.
• Vaccines: Developed ZyCoV-D, India’s first plasmid DNA COVID-19 vaccine; introduced VaxiFlu-4, India’s first quadrivalent influenza vaccine; maintains advanced R&D centers for flu and other vaccines.
• APIs & Contract Manufacturing: State-of-the-art API and finished-dosage facilities (largest in Moraiya), approved by global regulators; supports complex molecule manufacturing and exports to the US and Europe.
• Animal Health & Wellness: Leading provider of animal healthcare products and consumer wellness items, including drink mixes and skincare under Zydus Wellness.
• R&D & New Chemical Entities: Powered by ~1,400 researchers, the company has brought first-in-India molecule Lipaglyn to market and continues to innovate in oncology, inflammation, and NDDS.

Key Achievements or Milestones:

• 1952: Established, paving way as a science-driven medicine provider in India.
• 2007: Entered regulated biosimilars market with EU-approved Exemptia (adalimumab).
• 2013–2015: Brought Lipaglyn (for diabetic dyslipidemia) and sofosbuvir (SoviHep) to Indian patients.
• 2020–21: Launched ZyCoV-D, the world’s first plasmid DNA COVID-19 vaccine; also scaled up hydroxychloroquine and remdesivir production during the pandemic.
• 2022: Introduced VaxiFlu-4 quadrivalent flu vaccine and secured USFDA approval for multiple cancer therapies including Enzalutamide.
• Global presence: Owns 30+ manufacturing sites across India, Germany, Brazil, and the US; strengthened consumer healthcare after acquiring Heinz India’s wellness brands.

7. Wockhardt Ltd

Established in 1967 by Dr. Habil Khorakiwala, Wockhardt Ltd. is now a globally integrated pharma and biotech leader based out of Mumbai. From being a generic drug company, the firm diversified substantially over the decades. Currently, Wockhardt functions across branded and generic formulations, active pharmaceutical ingredients (APIs), biopharmaceuticals, vaccines, and even healthcare services through its super-specialty hospital chain.

Its unique edge is its integrated strategy—ranging from innovative recombinant insulin treatments and patented delivery systems, to manufacturing new antibiotics for multi-drug-resistant diseases, to supplementing global public health initiatives through vaccine fill-finish operations. 

Key Products/Services:

• Insulin & Diabetes Care: Introduced India’s first recombinant human insulin and insulin glargine, along with patented insulin pen delivery systems.
• Formulations & Biologics: Offers therapies across various specialties including pain management, nephrology, cardiology, neurology, and anti-infectives.
• APIs & Vaccines: Manufactures high-quality APIs and has developed vaccines such as BIOVAC-B for hepatitis B. Also involved in global vaccine fill-finish operations.
• Novel Antibiotics & R&D: Focused on developing new chemical entities to combat antimicrobial resistance. Several of its antibiotic candidates have received fast-track designation from international regulators.

Key Achievements or Milestones:

• 1972: Launched Proxyvon, India’s first combination pain relief drug.
• 1979: Introduced Betadine (Povidone-Iodine) to the Indian market.
• 1995: Entered biotechnology and IV fluid production.
• 2000–2007: Expanded globally through acquisitions in the UK, US, and France.
• 2005: Launched India’s first automatic insulin delivery pen.
• Built six FDA/EMA/MHRA-approved manufacturing plants and three R&D centers.
• Contributed significantly during the COVID-19 pandemic by supporting vaccine fill-finish services for global pharmaceutical partners.
• Between 2022–2024: Advanced its antibiotic R&D pipeline with key collaborations and continued focus on combating drug-resistant infections.

8. Panacea Biotec Ltd.

Panacea Biotec Ltd., founded in 1984 and headquartered at New Delhi, is amongst India’s leading biotech and pharmaceutical firms, renowned for its pioneering work on vaccine and specialty therapeutics. With a legacy of innovation and commitment to public health, Panacea has been at the forefront of contributing towards worldwide immunization, such as the mass production of oral polio vaccines and India’s first fully liquid pentavalent and hexavalent combination vaccines.

Panacea’s manufacturing facilities, situated at various locations in Himachal Pradesh, Punjab, and Delhi, are renowned for world-class standards and approvals from leading global regulators. 

Key Products/Services:

• Vaccines: A global supplier of oral polio vaccines (tOPV, mOPV, bOPV), Panacea is known for launching EasyFive, India’s first fully liquid pentavalent vaccine, and EasySix, a hexavalent vaccine that combines protection against six deadly diseases in one shot. The company continues to innovate with pipeline candidates for dengue, hepatitis A, pneumococcal, and other next-gen vaccines.
• Pharmaceutical Formulations: Panacea’s pharma division offers treatments in organ transplantation (tacrolimus, mycophenolate mofetil), diabetes, oncology, nephrology, and gastrointestinal care. It is credited with developing PacliAll, the world’s first generic version of Abraxane using advanced nano-formulation technology.
• Biosimilars & Specialty Medicines: Actively developing biosimilars for complex biologics, Panacea also has a strong presence in niche therapy areas. Its formulations are exported to over 50 countries, especially in Latin America, CIS, Africa, and Southeast Asia.

Key Achievements or Milestones:

• 2005: Launched EasyFive, India’s first WHO-prequalified, fully liquid pentavalent vaccine.
• 2011: Developed and introduced PacliAll, a nano-formulation for cancer treatment.
• 2013: Reinstated WHO pre-qualification for its vaccines after regulatory upgrades.
• 2017: Rolled out EasySix, a hexavalent vaccine combining DTwP-HepB-Hib-IPV antigens.
• 2021: Partnered in the production of the Sputnik V COVID-19 vaccine during the pandemic.
• 2022–2023: Secured major global supply contracts with international health agencies; launched EasyFourPol and expanded global vaccine reach. 

9. Jubilant Pharmova Ltd.

Established in 1978 and belonging to the Jubilant Bhartia Group, Jubilant Pharmova Ltd. is a top Indian multinational life sciences company with a diversified presence across contract research, radiopharmaceuticals, allergy immunotherapy, pharmaceuticals, sterile manufacturing, and new drug discovery.

Its headquarters is in Noida, and it has over 65 countries with healthcare systems as customers, and it has over 5,500 professionals working for it across its operations. During the years, Jubilant has grown from a chemical manufacturing firm (previously called Vam Organics) to a respected international healthcare partner.

Key Products/Services:

• Radiopharmaceuticals: Manufactures and distributes both diagnostic and therapeutic radiopharmaceuticals, supported by a vast radiopharmacy network in the U.S.
• Generics & APIs: Produces a wide range of generic oral solid dosage forms and APIs through multiple regulatory-approved facilities across India.
• Sterile Injectables & Allergy Immunotherapy: Offers sterile manufacturing services for liquids and semi-solids along with standardized allergenic and venom extracts for immunotherapy.
• CRDMO Services: Provides end-to-end drug discovery and development solutions through Jubilant Biosys and other arms, offering capabilities in in-vitro biology, ADME, and custom synthesis.
• Proprietary Novel Drugs: Through Jubilant Therapeutics, focuses on developing targeted oral therapies for oncology, neuro-inflammation, and autoimmune disorders.

Key Achievements or Milestones:

• Transitioned from Vam Organics to Jubilant Life Sciences, and rebranded as Jubilant Pharmova in 2021 to reflect its life sciences focus.
• Built one of the largest radiopharmacy networks in the U.S., with over 50 facilities serving major healthcare providers.
• Successfully scaled up sterile injectable and generic drug manufacturing with USFDA and EMA-approved facilities.
• Achieved Voluntary Action Indicated (VAI) classification from the USFDA for its Roorkee solid-dose facility, enhancing its credibility in global markets.
• Demonstrated strong financial growth in recent years, with significant revenue contributions from the radiopharma segment.
• Strengthened its CRDMO vertical and invested in expanding its discovery pipeline for complex disease areas, especially cancer and chronic inflammatory conditions.

10. Genexis Biotech Pvt. Ltd.

Genexis Biotech Pvt. Ltd., incorporated in 2019 and having its headquarters at Vadodara, Gujarat, is a cutting-edge biotechnology firm that is redefining the development and delivery of biologics with the strength of precision fermentation.

Focused keenly on innovation and sustainability, Genexis operates as a company that develops animal-origin-free recombinant proteins, growth factors, and cell culture media, thus providing ethical and scalable options for conventional biomanufacturing. The firm mainly serves industries like regenerative medicine, biopharma, cellular agriculture, cosmetics, and food technology.

Key Products/Services:

• Animal-Free Growth Factors: Biologically active proteins designed to support cell proliferation and differentiation for use in stem cell therapy, tissue engineering, and cultivated meat.
• Serum-Free Culture Media: Alternatives to fetal bovine serum (FBS), offering high-performance, chemically defined media formulations that are reproducible and completely animal-free.
• Animal-Origin-Free Recombinant Proteins: Includes critical proteins such as albumin, collagen, fibronectin, transferrin, and vitronectin—all produced using microbial systems for high purity and consistency.
• Custom Protein & Reagent Solutions: Offers tailor-made production of cell culture reagents, viral transport media, detachment solutions, antibiotics, and electrophoresis buffers for R&D and industrial use.
• Strain Engineering & Bioprocess Scale-Up: Provides technical expertise in designing microbial strains, optimizing fermentation conditions, and scaling up production from lab to pilot and commercial levels.

Key Achievements or Milestones:

• Featured at Global Bio India 2024 as a leading innovator in the field of animal-free biomanufacturing.
• Entered into strategic collaboration with the Government of Gujarat to promote sustainable protein production through biotechnology.
• Secured several national awards, including runner-up positions in major innovation challenges and startup competitions across India.
• Recognized by top academic institutions such as IIT Kharagpur and IIT Mandi for breakthrough technologies and entrepreneurial excellence.
• Selected among the top biotech startups in multiple national contests for its impact-driven, cruelty-free approach to biotech innovation.

Conclusion

India’s biotech industry is one of the world’s leading agents of innovation, with a solid base established on scientific capability, friendly government policy, and a successful startup culture. As the nation continues to ramp up its capabilities in vaccine manufacture, genomics, bio-agriculture, and bioinformatics, it is increasingly becoming a biotech power in the making.

The leading biotech firms profiled on this blog are not only market leaders but also the principal drivers of this evolution. With innovative research, international collaborations, and reproducible solutions, these firms are designing the future of healthcare, sustainability, and industrial technology—both in India and globally. As a student, investor, or budding entrepreneur, monitoring these trailblazers provides insightful information regarding the future of biotechnology in India.

FAQs

1. Are Indian biotech firms taking in freshers?

Yes, some of the biotech companies like Biocon, Panacea Biotec, Syngene, and Zydus Lifesciences provide entry-level positions in R&D, quality assurance, and production. Startups also have research internships and trainee programs.

2. Can I invest in Indian biotech firms?

Yes, several of India’s top biotech companies like Biocon and Dr. Reddy’s Laboratories are listed on the public exchanges. Others have venture capital or private equity offerings, particularly in the startup sector.

3. What kind of qualifications are required to be employed by a biotech firm in India?

Most biotech jobs need at least an M.Sc. or B.Sc. in Biotechnology, Microbiology, Biochemistry, or Life Sciences. For research and senior posts, a Ph.D. or M.Tech is generally preferred. Extra skills in bioinformatics, data analysis, or clinical research will enhance your profile.

4. What are some significant biotech startups in India?

Leading startups are Bugworks Research (antibiotic resistance), String Bio (waste-to-protein technology), Sea6 Energy (marine biotechnology), and Eyestem (cell therapy). These startups are making headlines worldwide with their innovative research.

5. What is BIRAC and how does it support biotech startups?

BIRAC (Biotechnology Industry Research Assistance Council) is a government organization that provides funding, mentoring, incubation facilities, and grants such as BIG (Biotechnology Ignition Grant) to early-stage biotechnology ventures.